Wells Fargo Downgrades Zymeworks to Equal-Weight, Maintains Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo has downgraded Zymeworks from Overweight to Equal-Weight, maintaining the price target at $12.
November 01, 2024 | 11:25 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Wells Fargo has downgraded Zymeworks from Overweight to Equal-Weight, maintaining the price target at $12.
The downgrade from Overweight to Equal-Weight by Wells Fargo suggests a less bullish outlook on Zymeworks, which could lead to a negative short-term impact on the stock price. The maintained price target indicates no expected change in valuation, but the downgrade itself may influence investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100